How I treat patients with a history of heparin-induced thrombocytopenia
Open Access
- 21 July 2016
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 128 (3), 348-359
- https://doi.org/10.1182/blood-2016-01-635003
Abstract
Heparin-induced thrombocytopenia (HIT) is a relatively common prothrombotic adverse drug reaction of unusual pathogenesis that features platelet-activating immunoglobulin G antibodies. The HIT immune response is remarkably transient, with heparin-dependent antibodies no longer detectable 40 to 100 days (median) after an episode of HIT, depending on the assay performed. Moreover, the minimum interval from an immunizing heparin exposure to the development of HIT is 5 days irrespective of the patient’s previous heparin exposure status or history of HIT. This means that short-term heparin reexposure can be safely performed if platelet-activating antibodies are no longer detectable at reexposure baseline and is recommended when heparin is the clear anticoagulant of choice, such as for cardiac or vascular surgery. The risk of recurrent HIT 1 to 2 weeks after heparin reexposure is ∼2% to 5% and is attributable to formation of delayed-onset (or autoimmune-like) HIT antibodies that activate platelets even in the absence of pharmacologic heparin. Some studies suggest that longer-term heparin reexposure (eg, for chronic hemodialysis) may also be reasonable. However, for other antithrombotic indications that involve patients with a history of HIT (eg, treatment of venous thromboembolism or acute coronary syndrome), preference should be given to non-heparin agents such as fondaparinux, danaparoid, argatroban, bivalirudin, or one of the new direct-acting oral anticoagulants as appropriate.This publication has 52 references indexed in Scilit:
- Intraoperative anticoagulation and limb amputations in patients with immune heparin‐induced thrombocytopenia who require vascular surgeryJournal of Thrombosis and Haemostasis, 2012
- Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromesExpert Opinion on Drug Safety, 2009
- Management of anticoagulation in patients with subacute heparin-induced thrombocytopenia scheduled for heart transplantationBlood, 2008
- Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT)Thrombosis and Haemostasis, 2008
- Clinical sample investigation (CSI) hematology: pinpointing the precise onset of heparin‐induced thrombocytopenia (HIT)Journal of Thrombosis and Haemostasis, 2007
- Use of the pentasaccharide fondaparinux as an anticoagulant during haemodialysisThrombosis and Haemostasis, 2007
- Expert Opinion on Pharmacotherapy, 2005
- Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin‐dependent antibodiesBritish Journal of Haematology, 2005
- Use of Heparin during Cardiopulmonary Bypass in Patients with a History of Heparin-Induced ThrombocytopeniaThe New England Journal of Medicine, 2000
- Fatal effect of re-exposure to heparin after previous heparin-associated thrombocytopenia and thrombosisThe Lancet, 1990